Pontifax Management 4 G.P. (2015) Ltd. - 12 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Reporting relationship: 10%+ Owner
Issuer ticker: LBRX on Nasdaq
Reported as of: 12 Sep 2025
Net transaction value: +$15,000,000
SEC form: 4
Accepted by SEC: 16 Sep 2025, 16:15:07 UTC
Prior SEC filing: 11 Sep 2025
Next SEC filing: 17 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Asaf Shinar, CFO

Key filing fact

Pontifax Management 4 G.P. (2015) Ltd. filed Form 4 for LB PHARMACEUTICALS INC on 16 Sep 2025.

Key facts

This page summarizes Pontifax Management 4 G.P. (2015) Ltd.'s Form 4 filing for LB PHARMACEUTICALS INC.
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Sep 2025, 16:15.

Change

Previous filing in this sequence was filed on 11 Sep 2025.
Current net transaction value: +$15,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726334 Primary reporting owner

Pontifax Management 4 G.P. (2015) Ltd.

Relationship: 10%+ Owner
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Asaf Shinar, CFO
Signature date: 16 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LBRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +411,681
Change %
Price
Shares after: 411,681
Date: 12 Sep 2025
Ownership: See footnote
Footnotes: F1, F2

LBRX transaction

Common Stock

Purchase

Transaction value: $15,000,000
Shares: +1,000,000
Change %: +243%
Price: $15.00
Shares after: 1,411,681
Date: 12 Sep 2025
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -10,000,000
Change %: -100%
Price
Shares after: 0
Date: 12 Sep 2025
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 411,681
Exercise price
Footnotes: F1, F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Pontifax Management 4 G.P. (2015) Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.

Footnote F2

Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

Footnote F3

Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

Footnote F4

Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.